Sanofi aims to sell Allegra plant ahead of 2016 shutdown

By Gareth Macdonald contact

- Last updated on GMT

Sanofi to sell Kansas Allegra plant
Sanofi to sell Kansas Allegra plant
Sanofi has confirmed it wants to sell the Kansas City facility at which it makes the allergy drug Allegra (Fexofenadine).

Unconfirmed reports this week suggested the French drugmaker Sanofi had decided to sell the Kansas City plant and hired a commercial real estate agent to help it find a buyer.

A Sanofi spokeswoman confirmed the report, telling in-Pharmatechnologist.com that plan is to sell “both the equipment and the site itself.​”

She also confirmed that the facility produces the allergy treatment Allegra (Fexofenadine) and a number of other pharmaceutical products.

The site has been earmarked for closure since 2009​ when Sanofi said that falling demand for the drug made continued operation of the facility economically unviable.

Since then Sanofi has been gradually laying of the 390 staff employees at the site and reducing manufacturing levels.

According to an official statement emailed to this publication “all manufacturing will cease by August 2016, and we intend to sell both the building and manufacturing equipment​.”

Related news

Related products

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 13-Jul-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Related suppliers

Follow us

Products

View more

Webinars